Pair page
BPC-157 with TB-500 Fragment 17-23
Mechanism-tag overlap and published literature for BPC-157 and TB-500 Fragment 17-23, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
cytoprotectiontissue-repair
actin-binding-domainthymosin-4-active-fragment
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying BPC-157 and TB-500 Fragment 17-23 have published these mechanism-level observations. Not a co-administration recommendation.
The 7-amino-acid actin-binding domain of Tβ4. A leaner, lower-cost alternative to full-length TB-500 for users who want the core cell-migration mechanism without the rest of the Tβ4 molecule. Sometimes paired with BPC-157 as a minimalist a BPC-157 + TB-500 co-administration.
The most common community pairing — a cost-reduced analog of the "a BPC-157 + TB-500 co-administration." BPC-157 contributes local VEGFR2/NO/FAK-mediated repair and anti-inflammatory signaling; LKKTETQ contributes systemic actin-binding cell-migration support. Mechanistic rationale is sound; combined clinical data in humans is not available.
Quick facts
BPC-157
TB-500 Fragment 17-23
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2025 | BPC-157 | Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID: 40756949. (544 articles screened, 36 studies included — the single most comprehensive systematic revie… PMID 40756949 | systematic review |
| — | BPC-157 | ClinicalTrials.gov. Study of PL 14736 in Subjects With Ulcerative Colitis. NCT05765058. | human trial |
| 2025 | BPC-157 | Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. PMID: 40131143. PMID 40131143 | human pilot |
| 2024 | BPC-157 | Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. | human pilot |
| 2020 | BPC-157 | Xu C, Sun L, Ren F, Huang P, Tian Z, Cui J, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. (Independent safety study in mice, rats, rabbits, and dogs — no LD1 identifie… | preclinical, in vivo |
| 2006 | BPC-157 | Krivic A, Majerovic M, Jelic I, Seiwerth S, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-989. PMID: 16583442. PMID 16583442 | preclinical, in vivo |
| 2003 | BPC-157 | Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. PMID: 14554208. PMID 14554208 | preclinical, in vivo |
| 2025 | BPC-157 | McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID: 40789979. PMID 40789979 | review |
| 2025 | BPC-157 | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025. | regulatory / registry |
| — | BPC-157 | USADA. BPC-157: Experimental Peptide Creates Risk for Athletes. U.S. Anti-Doping Agency. usada.org. | regulatory / registry |
| 2025 | BPC-157 | Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. PMID: 40005999. PMID 40005999 | research article |
| 2022 | BPC-157 | Vukojevic J, Milavic M, Perovic D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487. PMID: 34380875. PMID 34380875 | research article |
| 2023 | TB-500 Fragment 17-23 | Sosne G, Kim C, Kleinman HK. 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. Int J Mol Sci. 2023;24(1):554. (Full-length parent… | human trial, Phase 3 |
| 2017 | TB-500 Fragment 17-23 | Shaw G, Lee-Barthel A, Ross ML, Wang B, Baar K. Vitamin C-enriched gelatin supplementation before intermittent activity augments collagen synthesis. Am J Clin Nutr. 2017;105(1):136-143. PMID: 27852613. (Substrate-side adjunct reference.) PMID 27852613 | mechanism / discovery |
| 1981 | TB-500 Fragment 17-23 | Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci U S A. 1981;78(2):1162-1166. PMID: 6940133. (Parent molecule discovery.) PMID 6940133 | mechanism / discovery |
| 2025 | TB-500 Fragment 17-23 | WADA. 2025 Prohibited List. Section S2 — Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency. Thymosin β4 and derivatives prohibited since 2011. | regulatory / registry |
| 2025 | TB-500 Fragment 17-23 | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) under Section 503A / 503B. FDA.gov. Updated 2025. | regulatory / registry |
| 2015 | TB-500 Fragment 17-23 | Sosne G, Kleinman HK. Primary Mechanisms of Thymosin β4 Repair Activity in Dry Eye Disorders and Other Tissue Injuries. Invest Ophthalmol Vis Sci. 2015;56(9):5110-5117. PMID: 26241398. PMID 26241398 | research article |
| 2012 | TB-500 Fragment 17-23 | Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PMID: 22074294. PMID 22074294 | research article |
| 2010 | TB-500 Fragment 17-23 | Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144-2151. PMID: 20179146. (Defines which Tβ4 activities map to which short sequences.) PMID 20179146 | research article |
| 2010 | TB-500 Fragment 17-23 | Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179-189. PMID: 20536465. PMID 20536465 | research article |
| 2007 | TB-500 Fragment 17-23 | Smart N, Risebro CA, Melville AA, Moses K, Schwartz RJ, Chien KR, Riley PR. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182. PMID: 17108969. PMID 17108969 | research article |
| 2004 | TB-500 Fragment 17-23 | Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. PMID: 15037010. PMID 15037010 | research article |
| 2004 | TB-500 Fragment 17-23 | Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. PMID: 15565145. (Cardiac progenitor activity — not reproduced by fragm… PMID 15565145 | research article |
Related pair pages
More research context
Frequently asked
Have BPC-157 and TB-500 Fragment 17-23 been studied together?
Researchers have published mechanistic-level co-administration discussion of BPC-157 and TB-500 Fragment 17-23. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do BPC-157 and TB-500 Fragment 17-23 share?
BPC-157 and TB-500 Fragment 17-23 do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of BPC-157 and TB-500 Fragment 17-23?
BPC-157: Category 2 (reclassification pending). TB-500 Fragment 17-23: Research-only; no human trials. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on BPC-157 and TB-500 Fragment 17-23?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the BPC-157 profile and the TB-500 Fragment 17-23 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026